Global Prostate Cancer Diagnostics Market OverviewThe global prostate cancer diagnostics market is projected to grow at a CAGR of approximately 12% during the forecast period, driven by a combination ...
The Article by Tamim Niazi and colleagues1 on the Prostate Cancer Study 9 (PCS-9) investigated stereotactic body radiotherapy ...
Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...
Profound Medical Celebrates The Hong Center’s 200th Independent TULSA Procedure for Prostate Disease
Renowned urologist Dr. Mark Hong sets new global benchmark for urologist-led, MRI-guided prostate treatment, leading a growing movement toward incision-free prostate therapy ...
Melbourne man Ralph Markham’s life was transformed by love and, later, a devastating cancer diagnosis. Now, he is hoping new ...
Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology ...
New BPH module and clinical data reinforce the TULSA Procedure™’s versatility in prostate disease, superior patient benefits, and potential for mainstream adoption ...
The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).
What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...
Regeneron announced the FDA’s approval of two indications of Eylea HD, including an 8mg injection for patients with macular ...
Former President Joe Biden has sparked dementia fears after he appeared "confused" at ex-Vice President Dick Cheney's funeral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback